SRR9879289
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1317853 | GTEX | — | 0.921 |
| 2 | BS_MQCKXD60 | Glial-neuronal tumor NOS | — | 0.916 |
| 3 | 525b66e0-235a-4bf5-bc46-eb022d630115 | — | — | 0.912 |
| 4 | TCGA-63-A5MG-01A-12R-A27Q-07 | — | cohortSQ1 | 0.910 |
| 5 | X9cad7a78.ea9b.47b0.9d06.e5e696031cc3 | — | cohortA1 | 0.909 |
| 6 | TCGA-49-4512-01A-21R-1858-07 | — | cohortA1 | 0.905 |
| 7 | SRR1487825 | GTEX | — | 0.901 |
| 8 | SRR1390582 | GTEX | — | 0.899 |
| 9 | SRR1378155 | GTEX | — | 0.898 |
| 10 | TCGA-95-A4VP-01A-21R-A262-07 | — | cohortA3 | 0.895 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.510 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.430 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.430 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.420 | Remibrutinib | — uncovered |
| COAGULATION | 0.400 | Binimetinib | — uncovered |
| MYOGENESIS | 0.280 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.270 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.260 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.240 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.240 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.200 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.170 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.170 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.160 | Inavolisib | — uncovered |
| HYPOXIA | 0.120 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.110 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.100 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.040 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.010 | Inavolisib | — uncovered |